Cogent Biosciences Seeks Three FDA Approvals for Bezuclastinib
Cogent Biosciences is seeking FDA approval for bezuclastinib to treat GIST and systemic mastocytosis, targeting a combined US market opportunity of $5 billion.
At the UBS Global Biopharma Conference 2026, Cogent Biosciences announced it is seeking three separate FDA approvals for its lead drug, bezuclastinib. The medication targets gastrointestinal stromal tumor (GIST) and systemic mastocytosis. The company has established PDUFA dates of November 30, 2025, for second-line GIST, December 30, 2025, for non-advanced systemic mastocytosis, and June 29, 2027, for advanced systemic mastocytosis.
CEO Andrew Robbins described bezuclastinib as a more selective KIT mutant inhibitor than the current standard, AYVAKIT. He claimed the drug offers superior efficacy in reducing mutant cell burden and avoids the CNS toxicity associated with the existing therapy. While acknowledging concerns regarding liver toxicity and potential black box warnings, Robbins stated that liver monitoring is already standard for existing therapies and will not hinder commercial uptake.
Cogent estimates a combined U.S. market opportunity of approximately $5 billion, with expected monthly pricing between $40,000 and $50,000. To prepare for the launch, the company has hired 100 commercial staff and claims it can ship the product within three days of receiving regulatory approval.